OS Therapies
Update in progressOSTX (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
OS Therapies Incorporated is a clinical‑stage biopharmaceutical company developing treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off‑the‑shelf immunotherapy for osteosarcoma, and OST-tADC, an antibody–drug conjugate platform using a silicone dioxide linker with tunable, pH‑sensitive properties. Founded in 2018, the company is based in Grasonville, Maryland.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!